ifn-α-7

Resiquimod (R848) is an agonist of Toll-like receptors 7 and 8 (TLR7/TLR8) that induces the upregulation of cytokines including TNF-α, IL-6, and IFN-α. It possesses immunomodulatory, antitumor, and antiviral activities, and can be used to induce models of myocarditis and systemic lupus erythematosus (SLE).

TLR7 agonist21 (Compound 27B) is a selective activator of Toll-like receptor 7 (TLR7), with an EC50 of 17.53 nM for human TLR7 and 41.7 nM for mouse TLR7. It induces the secretion of pro-inflammatory cytokines, including IL-6, TNF-α, IFN-α1, and IL-4. Acting as a vaccine adjuvant, TLR7 agonist21 enhances IgG and IgA levels, offering protection for mice against influenza virus infection.

Anti-TLR7 Antibody is a humanized monoclonal antibody targeting Toll-like receptor 7 (TLR7). TLR7 is a pattern recognition receptor primarily located on endosomal membranes that recognizes single-stranded RNA (ssRNA), playing a pivotal role in antiviral immune responses and autoimmune diseases such as Systemic Lupus Erythematosus (SLE). This antibody specifically binds to TLR7, blocking its activation by ligands (e.g., viral RNA or synthetic agonists) and subsequently inhibiting the downstream MyD88-dependent signaling pathway and the production of Type I interferons (IFN-α/β). By modulating TLR7 signaling, Anti-TLR7 Antibody serves as a valuable tool for investigating viral infection mechanisms and therapeutic strategies for autoimmune disorders.